| Cytoxan ® (cyclophosphamide) and Revimmune |
For Systemic Scleroderma Lung Disease,
Pulmonary Fibrosis, Alveolitis, and Skin Fibrosis |
| Revimmune: Cyclophosphamide "Reboot" of Immune System |
| Revimmune articles and research studies. Accentia Biopharmaceuticals. |
| Revimmune Uses An Approved Drug In A New Patent-Pending Method To Eliminate Autoimmunity. Revimmune uses an ultra-high intensity, short-course of an intravenous formulation of an approved drug (cyclophosphamide), in a new patent-pending method to "reboot" a patient's immune system, thereby eliminating the autoimmunity. Medical News Today. 03/03/07. (Also see: Medications, and Autoimmune Diseases ) |
| SCOT Clinical Trial: Open Enrollment, 2005-2008 |
| SCOT Clinical Trial, which stands for "Scleroderma Cyclophosphamide Or Transplantation", will compare two potential therapies: autologous stem cell transplantation versus high-dose monthly cyclophosphamide. Study dates 2005-2008. (Also see: Scleroderma Clinical Trials: Current and Stem Cell Transplantation) Posted 10-12-05. |
| Northwestern University Clinical Trials |
| Allogeneic Hematopoietic Stem Cell Transplantation (NST) for Patients With Systemic Sclerosis. This study is designed to examine whether treating patients with high dose Cyclophosphamide and Fludarabine (drugs which reduce the function of your immune system) and CAMPATH-1H (a protein that kills the immune cells that are thought to be causing the disease), followed by return of blood stem cells that have been previously collected from patients brother or sister will stop or reverse the disease. (Northwestern) ClinicalTrials.gov. |
| Cyclophosphamide and rATG With Hematopoietic Stem Cell Support in Systemic Scleroderma. To evaluate the efficacy (phase II) of two treatment modalities: pulse cyclophosphamide versus high dose cyclophosphamide and rATG rescued with autologous peripheral blood stem cell transplantation. (Northwestern). ClinicalTrials.gov. |
| Postiive Results with Oral Cyclophosphamide |
| Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. One year of CYC improved lung function, skin scores, dyspnea, and health status/disability, effects which either persisted or increased further for several months after stopping therapy. However, except for a sustained impact on dyspnea, all of these effects waned and were no longer apparent at 24 months. PubMed. Am J Respir Crit Care Med. 2007 Nov 15;176(10):1026-34. (Also see: Medications and Pulmonary Involvement ) |
| Cyclophosphamide versus Placebo in Scleroderma Lung Disease. One year of oral cyclophosphamide for symptomatic scleroderma-related interstitial lung disease had a significant but modest beneficial effect on lung function, dyspnea, thickening of the skin, and the health-related quality of life. The New England Journal of Medicine. Volume 354:2655-2666:25, June 22, 2006. (Also see: Clinical Trials) |
| Outcomes at 24-months are Better for Patients Who Received One-year of Cyclophosphamide (CYC) Therapy for SSc Alveolitis Than in Those Who Received One-year of Placebo in the Scleroderma Lung Study. Differences between groups with respect to breathlessness, activities of daily living and general well-being were larger and favored CYC. Philip J. Clements. 1252 ACR 2006. (Also see: Pulmonary Fibrosis ) |
| Results of Cyclophosphamide versus Placebo in Scleroderma Lung Disease Study: Cyclophosphamide reduces dyspnea in scleroderma lung disease. Cyclophosphamide modestly reduces dyspnea and disability while improving measures of lung function. However, it is a potentially toxic drug and patients who take it require close monitoring. Cleveland Clinic Journal of Medicine, Vol. 73, No. 10, October 2006. |
| Oral cyclophosphamide (CYC) improves pulmonary function in scleroderma patients with fibrosing alveolitis: experience in one centre. Long-term therapy with oral CYC is effective in ameliorating or stabilising lung function in scleroderma patients with active alveolitis, with beneficial effects lasting up to 1 year after interruption. PubMed. Clin Rheumatol. 2006 Apr 14. (Also see: Pulmonary Fibrosis) |
| Cyclophosphamide Research for Systemic Sclerosis (Scleroderma) |
| High dose cyclophosphamide without stem cell rescue in scleroderma. High dose cyclophosphamide without stem rescue can lead to clinically significant improvement in skin score and measures of disease severity in patients with diffuse cutaneous scleroderma. PubMed. Ann Rheum Dis. 2007 Nov 1. (Also see: Diffuse Scleroderma and Medications ) |
| The Effect Of Cyclophosphamide Treatment On Skin Changes In Patients With Scleroderma Interstitial Lung Disease. Although the lot was small – only 28 patients- because they were treated with Cyclophosphamide according to their lung involvement, the Cyclophosphamide treatment seemed to ameliorate the skin thickening in Systemic Sclerosis. The effect is greater in those patients with higher mRodnanss. I. C. Oprisan. AB0518 EULAR 2007. (Also see: Skin Fibrosis and Pulmonary Fibrosis ) |
| Lupus Treatments Increase Risk of Infertility in Men. Men with systemic lupus erythematosus, especially those who begin treatment with intravenous cyclophosphamide after puberty, are at risk for sperm abnormalities associated with infertility. Medpage Today. 06/28/07. (Also see: Lupus and Male Infertility ) |
| Intermittent intravenous cyclophosphamide pulse therapy for the treatment of active interstitial lung disease associated with collagen vascular diseases. The efficacy and safety of our “divided administration” protocol of CYC for CVD-ILD was demonstrated. IngentaConnect. Modern Rheumatology, Volume 17, Number 2, April 2007, pp. 131-136(6). (Also see: Pulmonary Fibrosis ) |
| Combination of intravenous pulses of cyclophosphamide and methylprednizolone in patients with systemic sclerosis and interstitial lung disease. The results suggest that the employed combination is safe and effective, mainly in stabilizing the respiratory function of the patients. This goal is more realistic when treatment is given before significant functional compromise has ensued. PubMed. Rheumatol Int. 2007 Feb;27(4):357-61. (Also see: Pulmonary Fibrosis and Medications ) |
| Lung drug. Researchers at UCLA say cyclophosphamide, a drug typically used to treat cancer, may help slow down lung damage in scleroderma. Dr. Phillip Clements says there is a mild to modest benefit. It also softens the skin thickening, that many people have, and improves their function. WIStv. 02/21/07. (Also see: Pulmonary (Lung) Involvement ) |
| Predicting 24 Month Pulmonary Function Test, Modified Rodnan Skin Score (mRSS) and Functional Results from Baseline Measurements in the Cyclophosphamide versus Placebo Trial of Systemic Sclerosis (SSc) Alveolitis. This study suggests that 12 months of cyclophosphamide results in continued benefit at 24 months. Daniel E. Furst. 1130/389. ACR 2006. (Also see: Pulmonary Fibrosis, and Skin Fibrosis ) |
| High Dose Cyclophosphamide (CYC) Without Stem Cell Transplantation in Systemic Sclerosis. High dose CYC without stem cell transplantation leads to rapid improvement of the modified Rodnan skin, HAQ, and PGA scores in the severe early diffuse SSc. Christopher V. Tehlirian. 689 ACR 2006. (Also see: SCOT Clinical Trial, ASTIS Clinical Trial, and Skin Fibrosis ) |
| Intravenous cyclophosphamide (IVCYC) therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis (PM/DM). In this open-label study, IVCYC improved symptoms, pulmonary function tests and high-resolution computed tomography findings in patients with PM/DM. Rheumatology 2007 46(1):124-130. (Also see: Dermatomyositis ). |
| Long Term Pulmonary Function and Survival Outcomes of Scleroderma Patients treated with Cyclophosphamide for active interstitial lung disease. The majority of systemic sclerosis (SSc) patients who are treated with cyclophosphamide for active interstitial lung disease experience long-term lung function stability. However, around 1/3 continue to have lung function decline despite this therapy. Shikha Mittoo. F57/577 ACR 2006. (Also see: Pulmonary Fibrosis ) |
| Phase II: Cyclophosphamide and rATG With Hematopoietic Stem Cell Support in Systemic Scleroderma. To evaluate the efficacy (phase II) of two treatment modalities: pulse cyclophosphamide versus high dose cyclophosphamide and rATG rescued with autologous PBSCT. Northwestern University, Feinberg School of Medicine, Chicago, Illinois. ClinicalTrials.gov. |
| A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. No life-threatening or irreversible adverse reactions were observed in either group. This study showed that CYC is a promising disease modifying medication for SSc as it exhibited a positive influence on the evolution of disease. PubMed. Clin Rheumatol. 2005 Oct 14. |
| Cyclophosphamide reduces neutrophilic alveolitis in patients with scleroderma lung disease: a retrospective analysis of serial bronchoalveolar lavage investigations. Previous reports that patients with scleroderma lung disease with increased levels of granulocytes in BALF are more likely to benefit from treatment with intravenous cyclophosphamide are confirmed. PubMed. Ann Rheum Dis. 2005 Sep;64(9):1343-6. (Also see: Pulmonary Fibrosis) |
| Also See |
| Pulmonary Fibrosis. ISN. |
| Scleroderma Medical News. ISN. |
| Systemic Scleroderma Symptoms (Main list; treatments are listed on each symptom page.) ISN. |
| Scleroderma Treatments and Clinical Trials. ISN. |
| Skin Fibrosis. ISN. |
